SCHEMBL1169947

SCHEMBL1169947

N=c1n(Cc2cccc(C(F)(F)F)c2)c2ccccc2n1Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
MAPT P10636 3/20 0.54
MAPK10 P53779 1/20 0.54
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
PPARG P37231 4/20 0.48
TSHR P16473 1/20 0.48
TAAR1 Q96RJ0 1/20 0.46
TP53 P04637 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
SLC5A2 P31639 1/20 0.46
IDO1 P14902 1/20 0.45
CA12 O43570 1/20 0.45
CA9 Q16790 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
APOBEC3A P31941 1/20 0.44
NPBWR1 P48145 1/20 0.44
MCHR1 Q99705 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23241311 0.86 MAPT (0.51) LMNASMN1; SMN2MAPTMAPK10KDM4E
SCHEMBL11714353 0.82 TAAR1 (0.49) LMNASMN1; SMN2MAPTMAPK10KDM4E
SCHEMBL11716491 0.76 LMNA (0.70) LMNASMN1; SMN2MAPTMAPK10KDM4E
SCHEMBL1170484 0.75 LMNA (1.00) LMNASMN1; SMN2MAPTKDM4EALDH1A1
SCHEMBL21410873 0.75 HCRTR2 (0.82)
SCHEMBL21410871 0.75 HCRTR2 (0.82)
SCHEMBL28385561 0.75 PPARG (0.57) MAPTMAPK10ALDH1A1PPARGL3MBTL1
SCHEMBL4083104 0.75 TP53 (0.54) LMNASMN1; SMN2MAPTMAPK10ALDH1A1
SCHEMBL41778 0.74 TAAR1 (0.60) LMNAMAPTKDM4EALDH1A1GAA
SCHEMBL18001829 0.74 PPARG (0.55) LMNAMAPTMAPK10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2319512-A1 Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels. NeuroSearch AS (DK) 2011-05-11 EP claimed
US-20080200529-A1 Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels NEURO SEARCH A/S (DK) 2008-08-21 US claimed
EP-2319512-A1 Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels. NeuroSearch AS (DK) 2011-05-11 EP disclosed
US-20110034527-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS SOERENSEN ULRIK SVANE 2011-02-10 US disclosed
US-7842817-B2 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels NEUROSEARCH A/S (DK) 2010-11-30 US disclosed
EP-1838306-B1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH AS (DK) 2010-11-17 EP disclosed
US-20100280087-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS SOERENSEN ULRIK SVANE 2010-11-04 US disclosed
US-20080200529-A1 Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels NEURO SEARCH A/S (DK) 2008-08-21 US disclosed
EP-1838306-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2007-10-03 EP disclosed
WO-2006074991-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034527-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS KCNN2, KCNN1, KCNN3 LMNA 2521/4885SMN1; SMN2 2965/4885MAPT 1733/4885
US-20080200529-A1 Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels KCNN2, KCNN1, KCNN3 LMNA 2521/4885SMN1; SMN2 2965/4885MAPT 1733/4885
US-20100280087-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS KCNN2, KCNN1, KCNN3 LMNA 2521/4885SMN1; SMN2 2965/4885MAPT 1733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.